---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-062837"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T17:32:24.554859+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cellectar provides clinical updates, plans Phase 1 studies for CLR 125 and CLR 225 in H2 2025 subject to financing

## Summary
- CLR 125 (Auger-emitting PRC) Phase 1b study in triple-negative breast cancer planned for H2 2025, subject to additional financing.
- CLR 225 (alpha-emitting, actinium-225) Phase 1 imaging and dose-escalation safety study in solid tumors planned for H2 2025, subject to financing.
- CLOVER-WaM study of iopofosine I 131 in Waldenström macroglobulinemia met primary endpoint with MRR of 58.2% (p<0.0001), ORR 83.6%, and 7.3% CR rate.
- No treatment-related deaths in CLOVER-WaM study; most common Grade 3+ TRAEs were thrombocytopenia (81.5%) and neutropenia (66.2%), all patients recovered.
- Proposed securities offering to fund operating expenses and initiate CLR 125 and CLR 225 clinical studies.

## SEC filing metadata
- accession: 0001104659-25-062837
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465925062837/0001104659-25-062837-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465925062837/tm2519054d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-062837
- JSON: https://secwatch.observer/filing/0001104659-25-062837.json
- Plain text: https://secwatch.observer/filing/0001104659-25-062837.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.